Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSEPH W KIM

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1295913531
CMS profile
331552
Location
NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$3,374.14

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,250.00 2
Food and Beverage $124.14 2

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
EMD Serono, Inc. $1,750.00 1
Clovis Oncology, Inc. $1,500.00 1
Exelixis Inc. $66.73 1
Genentech, Inc. $57.41 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSEPH W KIM

NPI 1295913531 · CMS profile ID 331552

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295913531?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSEPH W KIM, NPI 1295913531, CMS profile ID 331552. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295913531?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JOSEPH W KIM, NPI 1295913531, CMS profile ID 331552. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295913531?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JOSEPH W KIM, NPI 1295913531, CMS profile ID 331552, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1295913531?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $3,374.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Clovis Oncology, Inc. $1,500.0009/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722235413 CMS
Genentech, Inc. $57.4102/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743037603 CMS
Exelixis Inc. $66.7302/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737174417 CMS
EMD Serono, Inc. $1,750.0002/10/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751287939 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,478.38 10
PY2020 $3,374.14 4
PY2021 $585.00 1
PY2022 $10,547.28 13
PY2023 $1,967.17 5
PY2024 $155.03 2
PY2025 $212.94 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $314.64 2
PY2025 Principal investigator $1,110,282.24 135
PY2024 Recipient $191.83 1
PY2024 Principal investigator $346,888.51 69
PY2023 Principal investigator $403,164.02 48
PY2022 Principal investigator $107,144.09 26
PY2021 Recipient $1,076.26 1
PY2021 Principal investigator $36,646.51 15
PY2020 Recipient $1,914.15 1
PY2020 Principal investigator $48,418.68 17
PY2019 Principal investigator $33,029.40 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

70 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,257.05 12/10/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082448008
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,300.00 12/06/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082447724
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,159.05 12/06/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082447728
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,019.10 12/06/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082447732
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $715.00 12/06/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082447734
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,240.00 12/06/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082447736
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.00 12/06/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082447738
Recipient Regeneron Pharmaceuticals, Inc. $191.83 12/03/2024 Covered Recipient Physician A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082395298
Principal investigator 1 ABBVIE INC. $5,000.00 11/28/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1100756957
Principal investigator 1 Exelixis Inc. $67,537.85 11/25/2024 Non-covered Recipient Entity
University of Kentucky Research Foundation
Phase II Clinical Trial Evaluating Cabozantinib and Pembrolizumab in Metastatic Pancreatic Cancer No dispute reported 06/30/2026 1138633481
Principal investigator 1 Genentech, Inc. $6,984.00 11/22/2024 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1133478735
Principal investigator 1 Exelixis Inc. $2,600.00 11/06/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634565
Principal investigator 1 Exelixis Inc. $1,300.00 11/06/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634567
Principal investigator 1 Exelixis Inc. $650.00 11/06/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634569
Principal investigator 1 Exelixis Inc. $3,250.00 11/06/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634571
Principal investigator 1 Genentech, Inc. $800.00 11/01/2024 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1133478733
Principal investigator 1 Genentech, Inc. $338.00 11/01/2024 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1133478741
Principal investigator 1 AstraZeneca Pharmaceuticals LP $34,887.00 10/16/2024 Non-covered Recipient Entity
YALE SCHOOL OF MEDICINE DEPARTMENT OF ORTHOPAEDICS AMD REHABILITATION
A Randomised,Double blind,Placebo controlled,Adaptive,Population Enrichment Phase III Study of AZD5305 in Men with Metastatic Castration sensitive Prostate Cancer Receiving Physician is Choice New Hormonal Agents No dispute reported 06/30/2026 1110842405
Principal investigator 1 Genentech, Inc. $1,200.00 10/16/2024 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1133478695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,203.10 10/10/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082440490
Principal investigator 1 Genentech, Inc. $4,142.00 09/25/2024 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1133478683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,203.10 09/24/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082439324
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,453.70 09/18/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082438264
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,392.10 09/18/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082438266
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,300.00 09/18/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082438268
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.00 09/18/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082438276
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,481.10 09/18/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082438278
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 09/12/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082437692
Principal investigator 1 Exelixis Inc. $1,450.00 07/15/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,826.92 07/10/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082431098
Principal investigator 1 ADC Therapeutics America, Inc. $347.75 07/05/2024 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1126522024
Principal investigator 1 ADC Therapeutics America, Inc. $3,882.29 07/05/2024 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1126522026
Principal investigator 1 ADC Therapeutics America, Inc. $1,379.30 07/05/2024 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1126522028
Principal investigator 1 ADC Therapeutics America, Inc. $654.69 07/05/2024 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1126522030
Principal investigator 1 ADC Therapeutics America, Inc. $3,479.29 07/05/2024 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1126522032
Principal investigator 1 ADC Therapeutics America, Inc. $298.61 07/05/2024 Non-covered Recipient Entity
Yale University
ADCT-901-101 No dispute reported 06/30/2026 1126522034
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.00 05/29/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082427431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,200.00 05/29/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082427439
Principal investigator 1 Merck Sharp & Dohme LLC $23,640.00 05/16/2024 Non-covered Recipient Entity
Yale Cancer Center
A Phase 1 Study of HMBD-002-V4C26 HMBD-002, a Monoclonal Antibody Targeting VISTS, as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced Solid Malignancies No dispute reported 06/30/2026 1136440686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.00 04/12/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082424441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,722.29 04/12/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082424451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 04/12/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082424487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,928.43 04/04/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082424201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 04/04/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082424257
Principal investigator 1 Exelixis Inc. $1,955.00 03/25/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634487
Principal investigator 1 Exelixis Inc. $1,788.00 03/25/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634491
Principal investigator 1 Exelixis Inc. $1,788.00 03/25/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634499
Principal investigator 1 Exelixis Inc. $1,788.00 03/25/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634509
Principal investigator 1 Exelixis Inc. $1,788.00 03/25/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634513
Principal investigator 1 Exelixis Inc. $390.00 03/25/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634515
Principal investigator 1 Genentech, Inc. $1,800.00 03/13/2024 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1133478603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $218.58 03/12/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082420141
Principal investigator 1 Exelixis Inc. $3,496.22 03/11/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634507
Principal investigator 1 Exelixis Inc. $2,564.12 03/04/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634489
Principal investigator 1 Exelixis Inc. $4,515.42 03/04/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634493
Principal investigator 1 Exelixis Inc. $4,822.22 03/04/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634495
Principal investigator 1 Exelixis Inc. $1,800.00 03/04/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634497
Principal investigator 1 Exelixis Inc. $1,361.10 03/04/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634501
Principal investigator 1 Exelixis Inc. $2,455.32 03/04/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634503
Principal investigator 1 Exelixis Inc. $3,565.19 03/04/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634505
Principal investigator 1 Exelixis Inc. $3,247.92 03/04/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138634511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 02/29/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082419121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 01/31/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082416181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.00 01/31/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082416183
Principal investigator 1 Genentech, Inc. $3,250.00 01/17/2024 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1133478593
Principal investigator 1 Genentech, Inc. $24,578.00 01/17/2024 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1133478597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,618.20 01/16/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082414009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,027.50 01/09/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082413765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 01/05/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082412947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 01/05/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION No dispute reported 06/30/2026 1082412949